Showing 291-300 of 9075 results for "".
Business Advisor: Protect Your Practice With Online Reputation Management Strategies
https://practicaldermatology.com/topics/general-topics/business-advisor-protect-your-practice-with-online-reputation-management-strategies/21943/Online communication has affected how patients view physicians and practices. Learn how to know who is saying what about you on the Internet and what to do about itClinical Focus: Psoriasis: New Data on Comorbidities Associated with Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-data-on-comorbidities-associated-with-psoriasis/21979/With data mounting, it is essential that dermatologists monitor all patients who may be at risk for comorbidities and provide referrals when indicated.Natural Ingredients and Their Applications in Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/natural-ingredients-and-their-applications-in-dermatology/22022/Understanding the role of natural ingredients in therapeutic regimens may help physicians to harness these agents for maximum effect.Business Advisor: Mapping Out a Price/Benefit Value Strategy for Your Practice
https://practicaldermatology.com/topics/general-topics/business-advisor-mapping-out-a-pricebenefit-value-strategy-for-your-practice/22043/Using a Price/Benefit map is a good way for practices to set prices and plan to adapt to changing markets.Expanding the Field: A New Botulinum Neurotoxin A Enters The US Arena
https://practicaldermatology.com/topics/general-topics/PD0609_07-php/22816/A cosmetic dermatologist with experience using Dysport describes how clinicians may approach the new agent in practice.Is Bone Mineral Density Testing Indicated with Long-Term IM Triamcinolone Acetonide Therapy?
https://practicaldermatology.com/topics/general-topics/PD1208_05-php/22603/Prospective data are lacking, but early findings suggest little if any risk of density-loss among patients on long-term therapy.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muCutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuThe Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,Mergers and Acquisitions in Derm and Aesthetics: Market Outlook
https://practicaldermatology.com/issues/september-2025/mergers-and-acquisitions-in-derm-and-aesthetics-market-outlook/37631/We took a deeper look into the dermatology and aesthetics mergers and acquisitions (M&A) market in a conversation with two of our team members, Drew Thomas and Jordan Frickle, who are closely involved in this sector. The following discussion brings together their perspectives on current trends,